Engineers Gate Manager LP Buys 15,557 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Engineers Gate Manager LP increased its Regeneron stake by 4,309.4% in the second quarter, purchasing 15,557 additional shares and bringing its holdings to 15,918 shares worth approximately $9.93 million.
• Regeneron reported a strong quarter, with EPS of $14.29 versus the $10.16 consensus estimate and revenue of $4.29 billion, up 16.7% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $802.18.
• Insiders sold 4,146 shares worth $3.43 million over the past 90 days, while the company faces investor litigation allegations related to disclosures surrounding its Fianlimab-Libtayo melanoma trial; the allegations remain unproven.

Engineers Gate Manager LP boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4,309.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,918 shares of the biopharmaceutical company's stock after purchasing an additional 15,557 shares during the period. Engineers Gate Manager LP's holdings in Regeneron Pharmaceuticals were worth $9,926,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Insigneo Advisory Services LLC grew its holdings in shares of Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company's stock worth $343,000 after purchasing an additional 13 shares during the last quarter. Arjuna Capital raised its holdings in Regeneron Pharmaceuticals by 3.2% during the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company's stock valued at $353,000 after buying an additional 14 shares during the last quarter. Guardian Wealth Advisors LLC NC boosted its position in Regeneron Pharmaceuticals by 3.3% during the 4th quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company's stock valued at $342,000 after buying an additional 14 shares during the period. TD Private Client Wealth LLC boosted its position in Regeneron Pharmaceuticals by 9.7% during the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company's stock valued at $130,000 after buying an additional 15 shares during the period. Finally, MCF Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 15 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur Ryan sold 200 shares of the firm's stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the transaction, the director owned 17,303 shares of the company's stock, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the sale, the director owned 603 shares in the company, valued at approximately $512,550. This trade represents a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,146 shares of company stock worth $3,432,488 in the last ninety days. 6.97% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Canaccord Genuity Group decreased their price objective on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a "buy" rating on the stock in a research report on Tuesday, May 19th. Piper Sandler dropped their target price on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating for the company in a report on Thursday, July 9th. Guggenheim raised their target price on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a "buy" rating in a research note on Monday, August 3rd. Leerink Partners boosted their price target on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a "market perform" rating in a report on Monday, August 17th. Finally, Benchmark raised Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 price target for the company in a research report on Tuesday, July 7th. Fourteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $802.18.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: HSBC raised its price target to $920 from $800 and maintained a Buy rating, implying additional upside based on the firm’s assessment of Regeneron’s prospects. HSBC price-target report
• Neutral Sentiment: A Wells Fargo healthcare-conference presentation and transcript offered investors additional management commentary, though the provided report does not identify a specific new catalyst. Wells Fargo healthcare conference transcript
• Neutral Sentiment: A report showing zero short interest is likely incomplete or erroneous, because it also reports a zero-day short-interest ratio and an undefined percentage change; it provides little actionable information for investors.
• Negative Sentiment: Several law firms repeated notices about a securities class action against Regeneron, with a September 14, 2026 lead-plaintiff deadline. The lawsuit concerns alleged failures to disclose risks surrounding the Phase 3 Fianlimab-Libtayo trial for melanoma, including statistical and protocol issues and possible effects of FDA Optimus-related amendments on progression-free-survival analysis. The allegations have not been proven. REGN class-action deadline notice
• Negative Sentiment: Reports that American Century Investments sold Regeneron shares may add to concerns about institutional conviction, although the available coverage does not provide the size or timing of the sale. American Century Investments sale report

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $793.26 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $859.34. The stock's 50 day simple moving average is $752.38 and its two-hundred day simple moving average is $720.15. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The stock has a market cap of $81.67 billion, a price-to-earnings ratio of 19.61, a PEG ratio of 1.58 and a beta of 0.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business's revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $12.81 EPS. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were issued a $0.94 dividend. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio is 9.29%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron's marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.